Report : Europe Epilepsy Drugs Market Forecast to 2030 - Regional Analysis - by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others)
At 3.8% CAGR, the Europe Epilepsy Drugs Market is Speculated to be Worth US$ 2,626.05 million by 2030, Says Business Market Insights
According to Business Market Insights' research, the Europe epilepsy drugs market was valued at US$ 1,941.16 million in 2022 and is expected to reach US$ 2,626.05 million by 2030, registering a CAGR of 3.8% from 2022 to 2030. Several epilepsy drugs nearing patent expiration and increasing product approvals are among the critical factor attributed to the Europe epilepsy drugs market expansion.
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.
Company | Patent | Patent Expiration Date | Ingredient | Treatment |
Sumitomo Pharma Co | US9206135 | April 21, 2026 | ESLICARBAZEPINE ACETATE | Partial-onset Seizures Epilepsy |
GlaxoSmithKline | US7919115 | January 4, 2029 | LAMOTRIGINE | Epilepsy |
Ucb Inc | USRE38551 | March 17, 2022 | Lacosamide | Epilepsy and Partial-onset Seizures |
SK Biopharmaceuticals | US7598279 | October 30, 2027 | CENOBAMATE | Partial Epilepsies |
SUPERNUS PHARMS | US8877248 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US9555004 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US10314790 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US8663683 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US9622983 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US8298580 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US8992989 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US8889191 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US9549940 | November, 2027 | Sustained-release formulations of Topiramate | Epilepsy |
SUPERNUS PHARMS | US8298576 | April, 2028 | Sustained-release formulations of Topiramate | Epilepsy |
On the contrary, recall of therapeutic products hampers the growth Europe epilepsy drugs market.
Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held 42.7% share of the Europe epilepsy drugs market in 2022, amassing US$ 829.38 million. It is projected to garner US$ 1,161.56 million by 2030 to expand at 4.3% CAGR during 2022–2030.
Based distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held 51.2% share of the Europe epilepsy drugs market in 2022, amassing US$ 994.70 million. It is projected to garner US$ 1,302.06 million by 2030 to expand at 3.4% CAGR during 2022–2030.
Based on country, the Europe epilepsy drugs market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK held 23.8% share of Europe epilepsy drugs market in 2022, amassing US$ 461.70 million. It is projected to garner US$ 664.36 million by 2030 to expand at 4.7% CAGR during 2022–2030.
Key players operating in the Europe epilepsy drugs market are Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA, among others.
- In September 2023; Sanofi sold Pharmanovia, a firm established in the United Kingdom, 11 brands from its portfolio related to the central nervous system, including the epilepsy medications Gardenal and Frisium. Eleven brands from Sanofi's portfolio related to the central nervous system, including the epilepsy medications Frisium and Gardenal, were transferred to Pharmanovia, a firm based in the UK. Along with Tercian, which treats anxiety and psychotic problems in patients who have already failed other medications, Sanofi is also getting rid of the epilepsy medication Gardenal and the nausea and vertigo medication Stemetil.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com